KRAS and breast cancer: BC cells commonly harbor PIK3CA, AKT1, and HRAS/KRAS mutations, as well as PTEN deletion/mutations [31], leading to the constitutive activation of proliferation-related pathways such as the PI3K/AKT and MAPK/ERK pathways.